Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults
- jeanfrancoismaison
- May 5
- 1 min read
top of page
Search
Recent Posts
See Allhttps://pubmed.ncbi.nlm.nih.gov/40467521/
https://pubmed.ncbi.nlm.nih.gov/40450523/
https://pubmed.ncbi.nlm.nih.gov/40464483/
bottom of page
Comments